Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Companies

Another US settlement for Takeda on Actos litigation, with Mylan

This article was originally published in Scrip

Executive Summary

Mylan has become the third company to settle outstanding litigation with Takeda Pharmaceutical regarding the antidiabetic Actos (pioglitazone), allowing it to market its generic version in the US on 17 August 2012, or earlier under certain circumstances. The other two generic firms that have settled are Ranbaxy and Watson (scripnews.com, 15 March 2010). All of the agreements are subject to review by the US Department of Justice and the Federal Trade Commission.

Table

View full table

Topics

Related Companies

Tags:
Companies
Latest Headlines

Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

Analysis: Novo And Lilly Make Their Money Work

AstraZeneca’s Hot Streak Whets Investor Appetite For What’s Next

Sweden's InDex To Stay Afloat Thanks To Mystery Merger Partner

See All
UsernamePublicRestriction

Register

SC007349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By